Intrarosa is owned by Millicent.
Intrarosa contains Prasterone.
Intrarosa has a total of 3 drug patents out of which 0 drug patents have expired.
Intrarosa was authorised for market use on 16 November, 2016.
Intrarosa is available in insert;vaginal dosage forms.
Intrarosa can be used as intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
The generics of Intrarosa are possible to be released after 19 March, 2031.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8629129||MILLICENT||Pharmaceutical compositions|| |
(5 years from now)
|US8957054||MILLICENT||Pharmaceutical compositions|| |
(6 years from now)
|US8268806||MILLICENT||Pharmaceutical compositions|| |
(8 years from now)
Market Authorisation Date: 16 November, 2016
Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic